ストックスクリーナーアプリを入手
0.6534
7.00%
0.0422
前日終値:
$0.6112
開ける：
$0.62
24時間の取引高:
1.55M
Relative Volume:
2.32
時価総額：
$38.36M
収益：
-
当期純損益:
$-123.46M
株価収益率:
-0.2523
EPS:
-2.59
ネットキャッシュフロー:
$-104.11M
1週間 パフォーマンス:
+46.01%
1か月 パフォーマンス:
+85.43%
6か月 パフォーマンス:
+89.62%
1年 パフォーマンス:
-64.07%
1日の値動き範囲:
$0.60
$0.659
1週間の範囲:
$0.4382
$0.659
52週間の値動き範囲:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
BCAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.6532 | 35.89M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.86 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.19 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.62 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
766.85 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
349.89 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-05-05 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-06-28 | 開始されました | ROTH Capital | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | BTIG Research | Buy |
| 2021-01-11 | 開始されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | JP Morgan | Overweight |
| 2021-01-11 | 開始されました | Jefferies | Buy |
すべてを表示
Bioatla Inc (BCAB) 最新ニュース
BioAtla stock holds Market Perform rating at JMP as FDA aligns on Phase 3 design - Investing.com
Risk adjusted return profile for BioAtla Inc. analyzedJuly 2025 Technicals & Fast Moving Stock Watchlists - Newser
When is the best time to exit BioAtla Inc.July 2025 Price Swings & Reliable Price Breakout Signals - Newser
Key metrics from BioAtla Inc.’s quarterly dataJuly 2025 Big Picture & Risk Controlled Daily Plans - Newser
Is BioAtla Inc. stock ready for a breakoutVolume Spike & Long-Term Safe Investment Plans - Newser
Is BioAtla Inc. stock reversal real or fakeWeekly Profit Summary & Risk Managed Investment Entry Signals - Newser
Will BioAtla Inc. rebound enough to break evenEarnings Overview Report & High Return Stock Watch Alerts - Newser
Will BioAtla Inc. benefit from macro trendsJuly 2025 Opening Moves & Short-Term High Return Ideas - Newser
Tools to monitor BioAtla Inc. recovery probabilityMarket Movers & Fast Gain Swing Trade Alerts - Newser
Earnings visualization tools for BioAtla Inc.Inflation Watch & Weekly Momentum Stock Picks - Newser
How to monitor BioAtla Inc. with trend dashboardsMarket Growth Report & Stepwise Trade Signal Implementation - Newser
Is BioAtla Inc. forming a breakout patternJobs Report & Long-Term Safe Investment Ideas - beatles.ru
FDA aligns with BioAtla on phase 3 trial design for cancer drug - Investing.com Canada
BioAtla announces outcomes from Type B FDA meeting on ozuriftamab vedotin - TipRanks
BioAtla Inc. Reversal Rally May Surprise BearsJuly 2025 Analyst Calls & Weekly Breakout Stock Alerts - beatles.ru
Short interest data insights for BioAtla Inc.Weekly Trend Recap & Technical Pattern Based Signals - Newser
Using economic indicators to assess BioAtla Inc. potential2025 Winners & Losers & Technical Entry and Exit Tips - Newser
BioAtla (NASDAQ:BCAB) Raised to Sell at Wall Street Zen - Defense World
BioAtla shares rise 4.28% premarket after updating FDA on ozuriftamab vedotin plan. - AInvest
BioAtla’s Ozuriftamab Vedotin and Its Pathway to Accelerated Approval in OPSCC: A Catalyst for Partnership and Valuation Inflection - AInvest
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA - GlobeNewswire
BioAtla updates FDA on ozuriftamab vedotin plan for OPSCC after positive Phase 2 results - MarketScreener
45% Cancer Response Rate: BioAtla's Oz-V Drug Gets FDA Green Light for Pivotal Trial in OPSCC - Stock Titan
Can BioAtla Inc. recover in the next quarterMarket Risk Summary & Reliable Intraday Trade Alerts - Newser
Tick level data insight on BioAtla Inc. volatilityMarket Growth Review & Low Volatility Stock Recommendations - Newser
Will BioAtla Inc. stock recover after earnings2025 Fundamental Recap & Safe Entry Zone Tips - خودرو بانک
Is BioAtla Inc. affected by consumer sentimentRecession Risk & Real-Time Chart Pattern Alerts - خودرو بانک
What is the next catalyst for BioAtla Inc.2025 AllTime Highs & Verified High Yield Trade Plans - خودرو بانک
Can BioAtla Inc. navigate macro headwinds2025 AllTime Highs & Daily Stock Trend Reports - خودرو بانک
What analysts say about BioAtla Inc. stockJuly 2025 WrapUp & Community Trade Idea Sharing - خودرو بانک
Will BioAtla Inc. benefit from AI trends2025 Technical Patterns & Technical Entry and Exit Tips - خودرو بانک
Does BioAtla Inc. stock benefit from AI growthEntry Point & Expert Curated Trade Ideas - خودرو بانک
Does BioAtla Inc. stock have upside surprise potential2025 Market WrapUp & Weekly Breakout Opportunity Watchlist - 강소기업뉴스
Risk Check: Is BioAtla Inc. affected by consumer sentimentWeekly Trend Summary & Long-Term Growth Plans - خودرو بانک
Combining price and volume data for BioAtla Inc.Quarterly Market Review & Community Consensus Trade Signals - Newser
Is BioAtla Inc. exposed to political riskMarket Growth Review & Real-Time Buy Signal Notifications - خودرو بانک
What BioAtla Inc (NASDAQ: BCAB) Stock Didn’t Tell You This Week - stocksregister.com
Combining machine learning predictions for BioAtla Inc.2025 Performance Recap & Reliable Volume Spike Trade Alerts - Newser
Will BioAtla Inc. stock go up in YEAR2025 Breakouts & Breakdowns & Risk Adjusted Buy/Sell Alerts - خودرو بانک
BioAtla Inc. stock momentum explained2025 Top Decliners & Daily Risk Controlled Trade Plans - Newser
Is it time to cut losses on BioAtla Inc.Trend Reversal & Safe Capital Allocation Plans - Newser
Building trade automation scripts for BioAtla Inc.July 2025 Sentiment & Safe Entry Point Alerts - Newser
Bioatla Inc (BCAB) 財務データ
収益
当期純利益
現金流量
EPS
1.68%
0.91%
大文字化:
|
ボリューム (24 時間):